Dr Mitchell Sojack, LCSW, PHD, MPA | |
1715 Sunken Rd, Fredericksburg, VA 22401-4534 | |
(540) 845-7683 | |
(540) 370-0110 |
Full Name | Dr Mitchell Sojack |
---|---|
Gender | Male |
Speciality | Social Worker - Clinical |
Location | 1715 Sunken Rd, Fredericksburg, Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1033788849 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YM0800X | Counselor - Mental Health | (* (Not Available)) | Secondary |
1041C0700X | Social Worker - Clinical | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Mitchell Sojack, LCSW, PHD, MPA 1715 Sunken Rd, Fredericksburg, VA 22401-4534 Ph: (540) 845-7683 | Dr Mitchell Sojack, LCSW, PHD, MPA 1715 Sunken Rd, Fredericksburg, VA 22401-4534 Ph: (540) 845-7683 |
News Archive
Researchers from the Federal Research and Clinical Centre of Physical-Chemical Medicine, and staff from MIPT's Systems Biology Laboratory, the Research Institute of Phthisiopulmonology and the St. Petersburg Pasteur Institute, conducted a large-scale analysis of the proteins and genomes of mycobacterium tuberculosis strains that are common in Russia and countries of the former Soviet Union and found features that provide a possible explanation for their epidemiological success.
Many companies in the cell therapy regenerative medicine market including Roche, Genzyme, Athersys, Miltenyi Biotec, Hospira, Lonza and Life Technologies will join ISCT to launch a series of new initiatives that will create greater strategic alignment within the industry and drive late stage clinical development.
GlaxoSmithKline has announced positive safety and efficacy results from RAISE (RAndomized placebo- controlled ITP Study with Eltrombopag), a Phase III study of Promacta (eltrombopag) in adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who had received one or more prior ITP therapies.
Researchers at the University of Massachusetts Medical School believe they may have found a new treatment for retinitis pigmentosa, a severe neurodegenerative disease of the retina that ultimately results in blindness. One of the more common retinal degenerative diseases, RP is caused by the death of photoreceptor cells and affects 1 in 4,000 people in the United States. RP typically manifests in young adulthood as night blindness or a loss of peripheral vision and in many cases progresses to legal blindness by age 40.
› Verified 9 days ago